News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Antisense Therapeutics Limited (ANP.AX) and TJAB Advance MS Drug


3/19/2013 2:45:04 PM

by Richard Daverman, PhD

March 19, 2013 -- Antisense Therapeutics, an Australian biopharma, has contracted with Pharmaron to conduct a toxicology study of ATL1102. The company hopes to stage a China Phase IIb trial of the MS drug in China in partnership with Tianjin International Joint Academy of Biotechnology and Medicine (TJAB). The two entities extended the deadline for establishing a JV to develop ATL1102 until September 30, 2013, More details....

Stock Symbol: (ASX: ANP)


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES